XXXX due to antithrombotic treatment for @entity64 .

@entity1 @entity64 @entity1163 @entity2896 @entity158 @entity272 @entity121 @entity1229
UNASSIGNED: The purpose of this study was to evaluate the incidence and clinical features of muscle haematoma in @entity64 @entity1 . Muscle haematomas are rare complications that occur during antithrombotic treatment for acute @entity64 . Clinical and laboratory records of @entity64 @entity1 with @entity121 in the last 3.5years were retrospectively reviewed. Muscular haematoma developed in three of 694 (0.4%) consecutive @entity1 with acute @entity64 who were admitted to our institution. In addition, one outpatient presenting with muscle haematoma was found during the same period. The types of haematomas were @entity2896 in two @entity1 and iliopsoas haematoma in the remaining two. All three acute @entity1 received both antiplatelet and anticoagulant therapies. The outpatient was treated with @entity1229 . Initial symptoms of haematoma included @entity158 (n=3) and @entity1163 (n=1). No @entity1 was correctly diagnosed at the onset of muscle haematoma. At initial examination of muscle haematoma, no @entity1 showed @entity272 . An ecchymosis developed in the abdominal area at an average of 3days after the initial symptoms. Mean decrease in haemoglobin was 6.8g/dL from baseline. None required surgery whereas two @entity1 required blood transfusion. Muscle haematomas in @entity64 patients receiving antithrombotic therapy are rare complications that are difficult to diagnose at onset. The possibility of muscle haematoma should be considered in @entity1 with @entity64 undergoing antithrombotic therapy and presenting with acute @entity158 and @entity1163 , even if skin manifestations or a palpable mass are lacking.
